The Cost Effectiveness Analysis of PD-1 And PD-L1 Agents Compared with Docetaxel for Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
Keyword(s):
2011 ◽
Vol 6
(12)
◽
pp. 2097-2103
◽
Keyword(s):
Keyword(s):
2004 ◽
Vol 22
(9)
◽
pp. 581-589
◽
Cost–effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer
2020 ◽
Vol 9
(18)
◽
pp. 1301-1309
Keyword(s):
The Cost
◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 41
(11)
◽
pp. 2308-2320.e11
◽
Keyword(s):